Shares of Exelixis, Inc. (NASDAQ:EXEL) ended Monday session in green amid volatile trading. The shares closed up +0.58 points or 4.10% at $14.74 with 11.77 million shares getting traded. Post opening the session at $14.72, the shares hit an intraday low of $14.17 and an intraday high of $14.95 and the price vacillated in this range throughout the day. The company has a market cap of $3.52 billion and the numbers of outstanding shares have been calculated to be 230.33 million shares.
Exelixis, Inc. (EXEL) provided an update on the timing of a key data presentation for cabozantinib at the European Society for Medical Oncology (ESMO) 2016 Congress, which is being held October 7-11, 2016 in Copenhagen, Denmark. Detailed results from CABOSUN, the randomized phase 2 clinical trial of cabozantinib compared with sunitinib in patients with previously untreated advanced renal cell carcinoma (RCC), has been selected for the Presidential Symposium 3 session on Monday, October 10, 2016, starting at 16:30 CEST (local Copenhagen time) / 10:30 a.m. EDT / 7:30 a.m. PDT.
The full logistical details for the CABOSUN data presentation are as follows:
Oral Presentation[LBA30_PR] “CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 Trial.”
Dr. Toni Choueiri, Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
Session: Presidential Symposium 3, Monday, October 10, 2016 – 16:30-18:10 CEST, Copenhagen room
Shares of Amedica Corporation (NASDAQ:AMDA) ended Monday session in red amid volatile trading. The shares closed down -0.030 points or 3.12% at $0.930 with 801,593.00 shares getting traded. Post opening the session at $0.99, the shares hit an intraday low of $0.93 and an intraday high of $1.00 and the price vacillated in this range throughout the day. The company has a market cap of $22.36 million and the numbers of outstanding shares have been calculated to be 23.58 million shares.
on Aug 24, 2016 Amedica Corporation ( NASDAQ : AMDA ), an innovative biomaterial company that develops and commercializes silicon nitride as a platform for biomedical applications, is pleased to announce the U.S. Food and Drug Administration (FDA) clearance of expanded Valeo® II Lateral Lumbar sizes. The additional sizes of the Valeo II LL interbody fusion device will be commercially available August 29, 2016.
The Valeo II LL interbody fusion device is made entirely of Amedica’s proprietary medical grade silicon nitride ceramic — an ideal material for fusion, due to its inherent osteoconductivity, anti-infective properties, bone-like imaging (artifact-free & radiotranslucent), and exceptional strength. The system includes second generation instrumentation to improve patient safety and surgeon ease of use.
“I’m delighted to announce the recent FDA clearance of our expanded silicon nitride lateral lumbar implant offerings,” said Dr. Sonny Bal, Chairman and Chief Executive Officer. “It’s estimated that lateral lumbar procedures will remain one of the fastest growing interbody fusion segments over the next five years. The minimally invasive nature of the procedure provides patients with benefits such as less blood loss, smaller incisions and shorter hospital and intraoperative times. We believe these clinical benefits, coupled with our unique silicon nitride biomaterial will lead to an improved continuum of care for individuals.”